Previous study demonstrated pioglitazone (a thiazolidinedione) is a peroxisome proliferator–activated receptor γ (PPARγ) agonist that improves steatosis, inflammation, and ballooning in patients with NAFLD [32]. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.